A Study Comparing Rituximab/Bendamustin(RB) Alternating With Rituximab/Bendamustin/Cytarabin(RBAC) With RB Therapy in Elderly Patients With Mentle Cell Lymphoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE2

Total Enrollment

90 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-10-18

Study Completion Date

2029-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a phase 2, multicenter, open-label, active-controlled randomized trial to determine efficacy and safety of rituximab/bendamustine (RB) alternating with rituximab/bendamustine/cytarabine (RBAC) compared with standard RB alone in the first-line treatment of elderly patients with mantle cell lymphoma, who are not eligible for high-dose therapy followed by autologous stem cell transplantation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Ibrutinib Combined With Bendamustine and Rituximab in Newly Diagnosed Mantle Cell Lymphoma Patients Who Aged > 65 Years

NCT05406154

Mantle Cell Lymphoma (MCL)

UNKNOWN

Immunochemotherapy With Rituximab-Bendamustine-Cytarabine (R-BAC) for Patients With Mantle Cell Lymphoma

NCT00992134

Lymphoma, Mantle-Cell

COMPLETED PHASE2

Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.

NCT00963534

Mantle Cell Lymphoma

COMPLETED PHASE1/PHASE2

S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma

NCT01412879

Lymphoma

COMPLETED PHASE2

Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma

NCT01661881

Mantle Cell Lymphoma

ACTIVE_NOT_RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Eligible patients will be randomly assigned to either the investigational treatment arm (RB alternating with RBAC) or the standard treatment arm (RB) in a 1:1 ratio. Patients will be stratified by age (≥70 years vs. 60-69), histologic morphology (blastoid/pleomorphic vs. non-blastoid/non-pleomorphic), and MIPI-C risk score (0/1 vs. 2/3).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mantle Cell Lymphoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

RB/RBAC alternating

Every 4 weeks for 6 cycles

RB (1st, 3rd, and 5th cycles)

* Rituximab + Bendamustine

RBAC (2nd, 4th, and 6th cycles)

* Rituximab + Bendamustine + Cytarabine

Group Type EXPERIMENTAL

RB/RBAC alternating

Intervention Type DRUG

Patients assigned to the RB alternating with RBAC arm will receive six cycles of alternating RB (odd cycles) or RBAC (even cycles)

RB (1st, 3rd, and 5th cycles)

* Rituximab 375mg/m2, IV, D1
* Bendamustine 90mg/m2, IV, D1-2

RBAC (2nd, 4th, and 6th cycles)

* Rituximab 375mg/m2, IV, D1
* Bendamustine 70mg/m2, IV, D2-3
* Cytarabine 500mg/m2, IV, D2-4

RB

Every 4 weeks for 6 cycles

\- Rituximab + Bendamustine

Group Type ACTIVE_COMPARATOR

RB

Intervention Type DRUG

Every 4 weeks for 6 cycles

* Rituximab 375mg/m2, IV, D1
* Bendamustine 90mg/m2, IV, D1-2

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

RB/RBAC alternating

Patients assigned to the RB alternating with RBAC arm will receive six cycles of alternating RB (odd cycles) or RBAC (even cycles)

RB (1st, 3rd, and 5th cycles)

* Rituximab 375mg/m2, IV, D1
* Bendamustine 90mg/m2, IV, D1-2

RBAC (2nd, 4th, and 6th cycles)

* Rituximab 375mg/m2, IV, D1
* Bendamustine 70mg/m2, IV, D2-3
* Cytarabine 500mg/m2, IV, D2-4

Intervention Type DRUG

RB

Every 4 weeks for 6 cycles

* Rituximab 375mg/m2, IV, D1
* Bendamustine 90mg/m2, IV, D1-2

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. newly diagnosed, previously untreated, histologically confirmed CD20+ mantle cell lymphoma, confirmed by WHO classification criteria
2. age ≥70 years or 60-69 years if the patients are ineligible for high-dose therapy with autologous stem cell transplantation.
3. ECOG performance status 2 or less
4. Adequate organ functions

* adequate heart function: LVEF ≥50% by echocardiography or MUGA
* adequate renal function: serum creatinine ≤ 2.0mg/dL or CrCl ≥40 mL/min based on the Cockcroft-Gault method
* adequate hepatic function: ≤2.5 times the upper limit of ALT (≤5 times the upper limit of ALT if the elevation is attributed by underlying lymphoma) and ≤2 times the upper limit of ALT (≤3 times the upper limit of total bilirubin if the elevation is attributed by underlying lymphoma)
* adequate hematologic function: absolute neutrophil counts (ANC) ≥ 1,500/mL, platelet counts ≥ 100,000/mL (any ANC and platelet counts are allowed, if they were related to bone marrow involvement)
5. Written informed consent

Exclusion Criteria

1. In-situ mantle cell lymphoma
2. Ann Arbor stage 1 disease
3. Prior treatment for Hodgkin lymphoma or non-Hodgkin lymphoma within the last 5 years.
4. Active malignancy within the past 3 years except for localized non-melanoma skin cancer, papillary thyroid cancer, cervical carcinoma in situ, breast cancer in situ, or localized prostate cancer that has been definitely treated,
5. Central nervous system involvement
6. HBsAg (+) or anti-HBc Ab (+) (patients will be eligible if they receive appropriate prophylactic antiviral therapy using entecavir, tenofovir, and so on)
7. History of prior hepatitis C infection (patients positive for HCV IgG will be eligible if they are negative for HCV-RNA)
8. Known history of human immunodeficiency virus (HIV) infection
9. any serious illness or medical conditions that are unstable or could jeopardize the safety of the patient and his/her compliance in the study

* Congestive heart failure ≥ NYHA class 3
* Acute coronary syndrome within 6 months (unstable angina or new-onset angina, myocardial infarct, or ventricular arrhythmia)
* History of significant neurological or psychological disorder including dementia and seizure disorder
* Severe chronic obstructive pulmonary disease with hypoxemia
* Cerebrovascular disease including transient ischemic attack within the past 6 months
* Non-healing wound, ulcer, or bone fracture
* Active uncontrolled bacterial, viral, or fungal infection requiring systemic therapy
10. concomitant administration of any other experimental drugs under investigation
11. Known hypersensitivity to bendamustine, rituximab, cytarabine, or mannitol
12. major surgical procedure or significant trauma within 28 days before start of study treatment, open biopsy within 7 days before start of study treatment
13. If the patient's partner is a woman who could possibly get pregnant, men who didn't have a vasectomy must agree to use medically recommended methods for adequate contraception (tubal ligation, intrauterine devices, or barriers \[diaphragm, cervical cap\] in the patient's partner and the use of condoms in men) when sexually active.

Minimum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No